Stock SCS STEM CELLS SPIN S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Stem Cells Spin S.A.

Equities

SCS

PLSTCLS00013

Biotechnology & Medical Research

End-of-day quote Warsaw S.E.
Other stock markets
 06:00:00 2024-07-04 pm EDT 		5-day change 1st Jan Change
0.378 PLN +0.53% Intraday chart for Stem Cells Spin S.A. -11.68% +11.18%
May. 15 Stem Cells Spin S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Feb. 14 Stem Cells Spin S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 10.75 23.56 78.54 29.56 11.57 14.05
Enterprise Value (EV) 1 11.99 24.69 79.51 29.89 11.97 14.16
P/E ratio -20.6 x -32.6 x 12,258 x -232 x 435 x -91.1 x
Yield - - - - - -
Capitalization / Revenue 20.5 x 40.5 x 293 x 56.2 x 46.6 x 33.5 x
EV / Revenue 22.9 x 42.4 x 296 x 56.8 x 48.2 x 33.8 x
EV / EBITDA 16.6 x -54.9 x 62.6 x 35.2 x 16.1 x -108 x
EV / FCF -1.4 x 9.91 x 92.1 x 12 x -6.87 x 16.1 x
FCF Yield -71.5% 10.1% 1.09% 8.31% -14.6% 6.23%
Price to Book 1.05 x 2.48 x 10.2 x 3.91 x 1.53 x 1.89 x
Nbr of stocks (in thousands) 41,337 41,337 41,337 41,337 41,337 41,337
Reference price 2 0.2600 0.5700 1.900 0.7150 0.2800 0.3400
Announcement Date 5/31/19 5/28/20 5/31/21 4/29/22 5/31/23 4/30/24
1PLN in Million2PLN
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 0.5244 0.5822 0.2683 0.5259 0.2484 0.4193
EBITDA 1 0.7215 -0.4499 1.27 0.8499 0.7454 -0.1315
EBIT 1 -0.4649 -0.7005 0.0417 -0.0768 -0.209 -0.1504
Operating Margin -88.66% -120.33% 15.55% -14.6% -84.14% -35.88%
Earnings before Tax (EBT) 1 -0.5217 -0.7232 0.006409 -0.1274 0.0266 -0.1543
Net income 1 -0.5217 -0.7232 0.006409 -0.1274 0.0266 -0.1543
Net margin -99.5% -124.22% 2.39% -24.23% 10.72% -36.81%
EPS 2 -0.0126 -0.0175 0.000155 -0.003082 0.000643 -0.003733
Free Cash Flow 1 -8.567 2.492 0.8635 2.484 -1.743 0.882
FCF margin -1,633.85% 428.03% 321.82% 472.36% -701.73% 210.35%
FCF Conversion (EBITDA) - - 67.99% 292.3% - -
FCF Conversion (Net income) - - 13,473.37% - - -
Dividend per Share - - - - - -
Announcement Date 5/31/19 5/28/20 5/31/21 4/29/22 5/31/23 4/30/24
1PLN in Million2PLN
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 1.24 1.13 0.97 0.34 0.4 0.11
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.717 x -2.51 x 0.7669 x 0.3972 x 0.5371 x -0.8288 x
Free Cash Flow 1 -8.57 2.49 0.86 2.48 -1.74 0.88
ROE (net income / shareholders' equity) -6.83% -7.35% 0.08% -1.67% 0.35% -2.06%
ROA (Net income/ Total Assets) -1.44% -2.41% 0.17% -0.29% -0.82% -0.66%
Assets 1 36.28 30.06 3.724 43.93 -3.249 23.32
Book Value Per Share 2 0.2500 0.2300 0.1900 0.1800 0.1800 0.1800
Cash Flow per Share 2 0 0 0 0.0100 0 0
Capex 1 10.4 - - - - 0.25
Capex / Sales 1,986.52% - - - - 59.01%
Announcement Date 5/31/19 5/28/20 5/31/21 4/29/22 5/31/23 4/30/24
1PLN in Million2PLN
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
STEM CELLS SPIN S.A. Stock Stem Cells Spin S.A.
+11.18% 3.95M
MODERNA, INC. Stock Moderna, Inc.
+18.97% 45.34B
LONZA GROUP AG Stock Lonza Group AG
+41.98% 40.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-10.06% 37.92B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+31.15% 31.75B
CELLTRION, INC. Stock Celltrion, Inc.
-7.79% 27.71B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.32% 26.52B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+43.05% 13.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.28% 12.44B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.41% 11.26B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. SCS Stock
  4. Financials Stem Cells Spin S.A.